Stockscreener 앱 받기
5.23
9.64%
0.46
시장 영업 전:
5.33
0.10
+1.91%
전일 마감가:
$4.77
열려 있는:
$4.82
하루 거래량:
1.92M
Relative Volume:
1.02
시가총액:
$741.84M
수익:
$288.95M
순이익/손실:
$-119.03M
주가수익비율:
-5.8079
EPS:
-0.9005
순현금흐름:
$60.67M
1주 성능:
+15.20%
1개월 성능:
-2.61%
6개월 성능:
-39.47%
1년 성능:
-16.32%
1일 변동 폭
$4.64
$5.25
1주일 범위
$4.38
$5.25
52주 변동 폭
$4.275
$11.55
마라바이 라이프 Stock (MRVI) Company Profile
명칭
Maravai Lifesciences Holdings Inc
전화
(858) 546-0004
주소
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
MRVI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
5.23 | 741.84M | 288.95M | -119.03M | 60.67M | -0.9005 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
마라바이 라이프 Stock (MRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 개시 | Guggenheim | Neutral |
| 2024-12-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-08 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | 개시 | Craig Hallum | Buy |
| 2023-12-12 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-08-08 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-01-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-11-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2020-12-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 개시 | Credit Suisse | Outperform |
| 2020-12-15 | 개시 | Goldman | Buy |
| 2020-12-15 | 개시 | Jefferies | Buy |
| 2020-12-15 | 개시 | Robert W. Baird | Outperform |
| 2020-12-15 | 개시 | Stifel | Buy |
| 2020-12-15 | 개시 | William Blair | Outperform |
| 2020-12-14 | 개시 | UBS | Buy |
모두보기
마라바이 라이프 주식(MRVI)의 최신 뉴스
Maravai LifeSciences Holdings, Inc. (MRVI) Stock: An Under $5 Gem with Biggest Upside Potential - Yahoo Canada Finance
12 Stocks Under $5 With Biggest Upside Potential - Insider Monkey
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap UpTime to Buy? - MarketBeat
Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 43%? - Simply Wall St
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Bought by Barclays PLC - Defense World
How the (MRVI) price action is used to our Advantage - Stock Traders Daily
Maravai LifeSciences Holdings (STU:MAR) Other Stockholders Equity : €0.0 Mil (As of Sep. 2024) - GuruFocus.com
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of “Hold” by Analysts - Defense World
Maravai LifeSciences (NASDAQ:MRVI) Stock Price Down 15.7%Here's What Happened - MarketBeat
Maravai LifeSciences projects FY revenue near mid-range guidance; shares fall - Investing.com Australia
Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI) - Defense World
Stock Traders Buy High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - MarketBeat
Maravai Lifesciences Holdings, Inc. Eliminates Andrew Burch as President, Nucleic Acid Production - Marketscreener.com
Maravai LifeSciences Holdings Projects 2024 Revenue Near Midpoint of Guidance - MarketWatch
Maravai LifeSciences Restructures Leadership Amid Revenue Update - TipRanks
Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue - The Manila Times
Maravai LifeSciences (MRVI) Announces In-Line Preliminary 2024 Revenue - StreetInsider.com
Maravai LifeSciences Expects 2024 Revenue to Hit Mid-Range of $255-265M Guidance - StockTitan
JPMorgan Chase & Co. Raises Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
JPMorgan Chase & Co. Has $33.66 Million Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Jane Street Group LLC Sells 201,787 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Sold by Jane Street Group LLC - MarketBeat
Principal Financial Group Inc. Reduces Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Principal Financial Group Inc. Has $2.93 Million Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Franklin Resources Inc. Takes $600,000 Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Acquired by Barclays PLC - Defense World
Geode Capital Management LLC Raises Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Geode Capital Management LLC Grows Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap DownHere's What Happened - MarketBeat
Investors Buy High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - Defense World
State Street Corp Sells 16,338 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Objective long/short (MRVI) Report - Stock Traders Daily
Maravai Lifesciences initiated with a Neutral at Guggenheim - Yahoo Finance
MRVI Stock Drops 5% Amidst Biotech Sector Decline - GuruFocus.com
Guggenheim starts Maravai LifeSciences stock with neutral rating - Investing.com
Danaher, Cryoport, Sartorius win Buy at Guggenheim (DHR:NYSE) - Seeking Alpha
Guggenheim starts Maravai LifeSciences stock with neutral rating By Investing.com - Investing.com UK
Guggenheim Initiates Coverage on Maravai LifeSciences (NASDAQ:MRVI) - MarketBeat
Exploring December 2024's Undervalued Small Caps With Insider Action In US - Simply Wall St
Maravai LifeSciences reduces debt by $228 million - Investing.com Australia
Maravai LifeSciences reduces debt by $228 million By Investing.com - Investing.com South Africa
Maravai LifeSciences (NASDAQ:MRVI) Stock Price Down 4.8%Time to Sell? - MarketBeat
Maravai LifeSciences (NASDAQ:MRVI) Trading Up 3.8%Here's Why - MarketBeat
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Brokerages - Defense World
Maravai LifeSciences' SWOT analysis: stock outlook amid mRNA manufacturing expansion - Investing.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.71 Million Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
The Manufacturers Life Insurance Company Has $490,000 Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Traders Purchase Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI) - MarketBeat
Charles Schwab Investment Management Inc. Has $7.87 Million Stock Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences' SWOT analysis: stock faces challenges amid growth potential - Investing.com Nigeria
마라바이 라이프 (MRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
마라바이 라이프 주식 (MRVI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HULL CARL | See Remarks |
Nov 11 '24 |
Buy |
5.64 |
175,000 |
987,000 |
175,000 |
| GTCR INVESTMENT XI LLC | Director |
May 28 '24 |
Sale |
9.81 |
9,940,974 |
97,570,660 |
20,150,005 |
4.81%
자본화:
|
볼륨(24시간):